ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. - Wikidata - wikimedia - TriplyDB

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

http://www.wikidata.org/entity/Q37307458

about

Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.Pharmacological and immunological targeting of tumor mesenchymalization.Critical role of glioma-associated oncogene homolog 1 in maintaining invasive and mesenchymal-like properties of melanoma cells Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator.Acetylsalicylic acid inhibits the growth of melanoma tumors via SOX2-dependent-PAF-R-independent signaling pathway.ZEB1 Promotes Oxaliplatin Resistance through the Induction of Epithelial - Mesenchymal Transition in Colon Cancer Cells.low neurotrophin receptor CD271 regulates phenotype switching in melanoma.miRNAs, Melanoma and Microenvironment: An Intricate Network.Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development.Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib.Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells.SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma.

P2860

Q36381496-64995603-9714-4C3A-A53D-3B577E29B70F Q37702322-68498098-A993-41CF-A36B-65C26C487756 Q38860973-7FFE08A8-4F14-4016-A3F9-F6EAF44591E2 Q39029043-87758FA0-3486-4E03-B820-F885D418D671 Q41247863-F8AA9BA7-BA5F-44A2-8C27-12F6539715DE Q41390229-6565B2F5-13BD-46F0-B1C2-471932672F8E Q41472852-3C1D3C1A-1419-443A-AD70-6C476D3AB3C6 Q44362145-6193BF29-19AE-4DC1-8640-6C51609CC8B0 Q47103221-4C252A77-71F7-42CC-95CA-BE72D47AEE26 Q47152593-0C438BE6-E86F-496A-9C05-153FF3AD5314 Q48090844-90DC0D25-97CE-4577-BE3B-4CBF716125A2 Q49900550-063889F8-2AFE-4AE5-8938-49EAF11F4AF1 Q52641587-94879ECE-31F8-4774-9E57-FA257E52DD98 Q53827045-49054F27-B913-4130-98E3-057AB5BE9116 Q54965855-0840F0F8-AD60-49B8-810E-628ACECAC4CD

P2860

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

http://www.wikidata.org/entity/Q37307458

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

@en

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

@nl

type

label

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

@en

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

@nl

prefLabel

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

@en

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

@nl

P1433

Q37307458-E666DBE7-4103-426F-9907-3FE660D2836E

P1476

Q37307458-F4F61DBB-91A1-40C9-8254-6EA271F54464

P2093

Q37307458-17AC8399-5017-4A31-9318-AF38FDA077F2

Q37307458-29E429BF-3686-4C9D-9908-D5E41DA624A7

Q37307458-457BA25F-6FD6-4DC3-8376-921F33AA44C0

Q37307458-5611FBC9-66FC-426F-8F15-6F0918E83200

Q37307458-9775D086-8386-497F-9E68-B2E2A6FBAB0E

Q37307458-BF45C470-6DA9-4FE2-917F-781DB9643E44

Q37307458-C4D25801-5CC7-483E-A37C-4A67C6CF4235

Q37307458-C9EBA705-D503-4438-9A17-B98475174AAA

Q37307458-E512979B-60FF-4219-923A-D74BEFE3F520

Q37307458-E593A2BA-0D85-4C0F-9AF0-6FBBC9697ADB

P2860

Q37307458-02484336-ABBA-44DA-88E4-5189C818E8E3

Q37307458-04E38E2F-1B06-41F9-868A-9CEB32BD5D55

Q37307458-0DE329A3-F51C-4D85-9551-792FEA1FA54F

Q37307458-0F66EDA9-9645-44E8-AE1F-37CBA40CE77D

Q37307458-1D4E91BD-7481-41EF-9DEA-8A99116BB029

Q37307458-1F759D7B-46C9-4635-9036-7208C9738183

Q37307458-2403DBE5-C564-4825-A2B5-D4A4D1C3B420

Q37307458-2D42A57E-0715-4815-9AF4-34050A0D5A4F

Q37307458-303D5CDA-6D7A-42BF-B8D6-68DA5ED66A65

Q37307458-32BB30DA-C660-4813-9F20-09D44F827399

P304

Q37307458-05296729-8D4A-4397-8EF7-BF77C372AD0F

P31

Q37307458-8FC8EA7A-4497-452B-8B51-0950FB296832

P356

Q37307458-2993485C-09B5-4B6D-935E-AF206B3E391A

P433

Q37307458-A92656A5-EEDD-4FF9-ABA6-744B53A69BE8

P478

Q37307458-AE5973D7-29C8-44E7-9667-7B20A13A2056

P50

Q37307458-0CF3AF53-9674-4EEA-930F-9F33D6190F17

Q37307458-59E4C5F0-599F-431F-870A-67E2DF583B41

Q37307458-5D3464B3-2D6A-4C17-B25C-BEF67A6D9180

Q37307458-AE1108D5-8E38-4626-B5E1-36AA7643A08E

Q37307458-B28E07D4-0EC9-4A99-9F7F-77A2EAE57192

Q37307458-B7BDC4FE-1D07-41DA-BBCF-2033B8DFD663

Q37307458-D03A49F6-0A46-4463-B49A-C726DEF91632

Q37307458-D94E69E2-32A6-4069-8872-4DDBF1823F74

P577

Q37307458-3E0D3EA0-D026-464E-9908-448B8B154FFD

P698

Q37307458-9FE4023F-B737-463B-A44D-74CD7AB4CD35

P932

Q37307458-FAC280C9-AD35-49E3-858C-F6BD3D2CB2C9

P356

P1433

EMBO Molecular Medicine

P1476

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

@en

P2093

Céleste Lebbé

http://www.w3.org/2001/XMLSchema#string

Emilie Thomas

http://www.w3.org/2001/XMLSchema#string

Garance Tondeur

http://www.w3.org/2001/XMLSchema#string

Geoffrey Richard

http://www.w3.org/2001/XMLSchema#string

Lauriane Depaepe

http://www.w3.org/2001/XMLSchema#string

Luc Thomas

http://www.w3.org/2001/XMLSchema#string

Marie Perier-Muzet

http://www.w3.org/2001/XMLSchema#string

Marie-Ambre Monet

http://www.w3.org/2001/XMLSchema#string

Maud Ligier

http://www.w3.org/2001/XMLSchema#string

Maxime Battistella

http://www.w3.org/2001/XMLSchema#string

P2860

Differential expression analysis for sequence count data

The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

Identification of cells initiating human melanomas

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Efficient tumour formation by single human melanoma cells

P304

1143-1161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15252/EMMM.201505971

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Corine Bertolotto

Arnaud de la Fouchardiere

Robert Ballotti

Stéphane Dalle

Stéphane Ansieau

P577

2016-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27596438

http://www.w3.org/2001/XMLSchema#string

P932

5048365

http://www.w3.org/2001/XMLSchema#string